ArticleClinical investigation2011
New considerations in the design of clinical trials for amyotrophic lateral sclerosis.
Article in Clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Value of Clinical Evidence and Health Economics and Outcomes Research (HEOR) Studies.Muscle & nerve · 2026Review
- ALS in Africa: current knowledge and exciting opportunities for future study - short communication.Annals of medicine and surgery (2012) · 2023Article
- MRI DTI and PDFF as Biomarkers for Lower Motor Neuron Degeneration in ALS.Frontiers in neuroscience · 2021Article
- Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials.Journal of neurology, neurosurgery, and psychiatry · 2019Article
- Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.British journal of clinical pharmacology · 2018Article
- Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.Clinical epidemiology · 2018Article
- Clinical Staging of Amyotrophic Lateral Sclerosis in Chinese Patients.Frontiers in neurology · 2018Article
- Measurement of spinal cord atrophy using phase sensitive inversion recovery (PSIR) imaging in motor neuron disease.PloS one · 2018Article
- Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS.Journal of neurology · 2017Article
- Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.Stem cells translational medicine · 2015Article
- Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Quantifying disease progression in amyotrophic lateral sclerosis.Annals of neurology · 2014Review
- The National ALS Registry: a recruitment tool for research.Muscle & nerve · 2014Article
- Moving forward in clinical trials for ALS: motor neurons lead the way please.Drug discovery today · 2014Review
- Gene therapy for misfolding protein diseases of the central nervous system.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Amyotrophic lateral sclerosis is a devastating neurodegenerative disease caused by loss of motor neurons. Its pathophysiology remains unknown, but progress has been made in understanding its genetic and biochemical basis. Clinical trialists are working to translate basic science successes into human trials with more efficiency, in the hope of finding successful treatments. In the future, new preclinical models, including patient-derived stem cells may augment transgenic animal models as preclinical tools. Biomarker discovery projects aim to identify markers of disease onset and progression for use in clinical trials. New trial designs are reducing study time, improving efficiency and helping to keep pace with the increasing rate of basic and translational discoveries. Ongoing trials with novel designs are paving the way for amyotrophic lateral sclerosis clinical research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.